Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.
- DOI
- 10.1182/bloodadvances.2025016208
- Published
- 2026 Jul 14
- Container
- Blood advances
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/bloodadvances.2025016208,
title = {Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.},
author = {Scheidegger N and Schneider C and Alexe G and Wang YC and Alonzo TA and Basanthakumar A and Bourgeois WA and Dudkiewicz-Garbicz J and Khalid D and Merickel LA and Perry JA and Ries RE and Salhotra S and Taillon A and Gamis A and Aplenc R and Harris MH and Wunderlich M and Armstrong SA and Pollard JA and Meshinchi S and Pikman Y and Stegmaier K},
year = {2026},
journal = {Blood advances},
doi = {10.1182/bloodadvances.2025016208},
url = {https://doi.org/10.1182/bloodadvances.2025016208}
}RIS
TY - JOUR TI - Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia. AU - Scheidegger N AU - Schneider C AU - Alexe G AU - Wang YC AU - Alonzo TA AU - Basanthakumar A AU - Bourgeois WA AU - Dudkiewicz-Garbicz J AU - Khalid D AU - Merickel LA AU - Perry JA AU - Ries RE AU - Salhotra S AU - Taillon A AU - Gamis A AU - Aplenc R AU - Harris MH AU - Wunderlich M AU - Armstrong SA AU - Pollard JA AU - Meshinchi S AU - Pikman Y AU - Stegmaier K PY - 2026 JO - Blood advances DO - 10.1182/bloodadvances.2025016208 UR - https://doi.org/10.1182/bloodadvances.2025016208 ER -
APA
N, S., C, S., G, A., YC, W., TA, A., A, B., WA, B., J, D., D, K., LA, M., JA, P., RE, R., S, S., A, T., A, G., R, A., MH, H., M, W., SA, A., JA, P., S, M., Y, P., & K, S. (2026). Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia.. Blood advances. https://doi.org/10.1182/bloodadvances.2025016208
Source records
- pubmed · retrieved 2026-09-26T02:32:46.985Z